However, despite the availability of multiple advanced medical therapies such as biologics and oral small molecules for the management of luminal CD, anti-TNF therapy was the only biological therapy that was systematically evaluated in phase 3 randomized controlled trials (RCTs) primarily designed for patients with perianal CD and remains preferred treatment of choice [3]. The gene discussed is TNF; the disease is Cowden disease.